- A randomized controlled trial (RCT) of patients with early triple-negative breast cancer (TNBC) has shown that 5-year DFS with adjuvant carboplatin plus taxane is noninferior to DFS with standard anthracycline plus taxane.
Why this matters
- Many patients with early TNBC cannot tolerate standard anthracycline-based chemotherapy, and alternative chemotherapy regimens are needed.
- Phase 2, multicenter RCT (N=308) of 6 cycles of TP (docetaxel or paclitaxel plus carboplatin) vs 4 cycles of EC-T (epirubicin and cyclophosphamide) followed by 4 cycles of T (docetaxel or paclitaxel).
- Primary outcome was DFS at 5 years posttherapy.
- Funding: Cancer Foundation of China; National Natural Science Foundation; other.
- Median follow-up was 66.9 months.
- 5-year DFS:
- 85.8% in EC-T group vs 84.4% in the TP group.
- The TP vs EC-T group was more likely to finish scheduled treatment (84.4% vs 75.4%; P=.047).
- The TP vs EC-T group had a lower frequency of grade 3/4 neutrocytopenia and alopecia (both P<.001 a higher frequency of grades thrombocytopenia>
- Imbalance in taxanes between groups, with more patients receiving docetaxel in the TP group than in the EC-T group.